ES2148063A1 - Proteina hibrida para utilizar en la liberacion dirigida de un compuesto a uan celula humana o animal. - Google Patents

Proteina hibrida para utilizar en la liberacion dirigida de un compuesto a uan celula humana o animal.

Info

Publication number
ES2148063A1
ES2148063A1 ES009800476A ES9800476A ES2148063A1 ES 2148063 A1 ES2148063 A1 ES 2148063A1 ES 009800476 A ES009800476 A ES 009800476A ES 9800476 A ES9800476 A ES 9800476A ES 2148063 A1 ES2148063 A1 ES 2148063A1
Authority
ES
Spain
Prior art keywords
particles
human
animal cell
utilizing
hybrid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009800476A
Other languages
English (en)
Other versions
ES2148063B1 (es
Inventor
Antonio Villaverde
Jordi X Feliu
Anna Aris
Andrew Knight
Richard P Harbottle
Antoni Benito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Original Assignee
Universitat Autonoma de Barcelona UAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Autonoma de Barcelona UAB filed Critical Universitat Autonoma de Barcelona UAB
Priority to ES9800476A priority Critical patent/ES2148063B1/es
Publication of ES2148063A1 publication Critical patent/ES2148063A1/es
Application granted granted Critical
Publication of ES2148063B1 publication Critical patent/ES2148063B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Molécula hibrida para utilizar en la liberación dirigida de un compuesto a una célula humana o animal. La invención se refiere a una molécula híbrida para utilizar en la liberación dirigida de un compuesto a una célula humana o animal. La molécula híbrida de la invención proporciona la posibilidad de liberar de manera dirigida un compuesto a una célula humana o animal sin utilizar la totalidad de las partículas de un virus infeccioso. Es especialmente ventajosa para el tratamiento médico de humanos y animales.
ES9800476A 1998-03-06 1998-03-06 Proteina hibrida para utilizar en la liberacion dirigida de un compuesto a una celula humana o animal. Expired - Fee Related ES2148063B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9800476A ES2148063B1 (es) 1998-03-06 1998-03-06 Proteina hibrida para utilizar en la liberacion dirigida de un compuesto a una celula humana o animal.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9800476A ES2148063B1 (es) 1998-03-06 1998-03-06 Proteina hibrida para utilizar en la liberacion dirigida de un compuesto a una celula humana o animal.

Publications (2)

Publication Number Publication Date
ES2148063A1 true ES2148063A1 (es) 2000-10-01
ES2148063B1 ES2148063B1 (es) 2001-04-16

Family

ID=8303008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9800476A Expired - Fee Related ES2148063B1 (es) 1998-03-06 1998-03-06 Proteina hibrida para utilizar en la liberacion dirigida de un compuesto a una celula humana o animal.

Country Status (1)

Country Link
ES (1) ES2148063B1 (es)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026412A1 (en) * 1994-03-28 1995-10-05 The Uab Research Foundation Ligands added to adenovirus fiber

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026412A1 (en) * 1994-03-28 1995-10-05 The Uab Research Foundation Ligands added to adenovirus fiber

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S.L. HART et al: "Cell Binding and Internalization by Filamentous Phage Displayng a Cyclic Arg-Gly-Asp-containing Peptide". THE JOURNAL OF BIOLOGICAL CHEMISTRY. 29 de abril de 1994, Vol. 269, no 17, paginas 12468-12474 *
T. JACKSON et al. "Arginine-Glycine-Aspartic Acid-Specific Binding by Foot-and-Mouth Disease Viruses to the Purified Integrin $\alpha$v$\beta$3 In Vitro". JOURNAL OF VIROLOGY. Noviembre 1997, Vol. 71, no 11, paginas 8357-8361. *

Also Published As

Publication number Publication date
ES2148063B1 (es) 2001-04-16

Similar Documents

Publication Publication Date Title
EP0952171A3 (en) Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
GB2357969A (en) Improvements in or relating to the treatment of lesions
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU5056196A (en) Hydrogel-forming, self-solvating absorbable polyester copolymers and methods for use thereof
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
AU6579498A (en) Compounds and methods for the diagnosis and treatment of (ehrlichia) infection
YU97402A (sh) Koštana (transkutalna) proteza
DE60121458D1 (de) Medizinische vorrichtung zur blutstromsteuerung
GR1002767B (el) Αντιπαρασιτικη συνθεση για την θεραπεια και την προστασια των ζωων συντροφιας.
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
DE69535349D1 (de) Implantierbare aktive medizinische Vorrichtung mit Mittel zur Unterscheidung zwischen Ruhe- bzw. Aktivzustand des Patienten
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
CZ20011581A3 (cs) Systém pro podávání bioaktivní sloučeniny inhalací
SE9600233L (sv) Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU8439998A (en) Compounds
WO1997011667A3 (en) Therapeutic applications using horse serum
EP0853486A3 (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
ES2148063A1 (es) Proteina hibrida para utilizar en la liberacion dirigida de un compuesto a uan celula humana o animal.
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
NZ512850A (en) Treatment of papillomavirus infections
AU2001232053A1 (en) System for the extracorporeal treatment of blood
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
TR200000249T2 (tr) Bir etki maddesinin deri üzerinden bir organizmaya geçirilmesi ve deri üzerine tatbik işlemine dair transdermal terapötik sistem (TTS)

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20001001

Kind code of ref document: A1

Effective date: 20001001

FD2A Announcement of lapse in spain

Effective date: 20180626